Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy DOI Creative Commons
Abdullah F. U. H. Saeed

Cells, Journal Year: 2025, Volume and Issue: 14(10), P. 741 - 741

Published: May 19, 2025

Tumor-associated macrophages’ (TAMs) origin, polarization, and dynamic interaction in the tumor microenvironment (TME) influence cancer development. They are essential for homeostasis, monitoring, immune protection. Cells from bone marrow or embryonic progenitors dynamically polarize into pro- anti-tumor M2 M1 phenotypes based on cytokines metabolic signals. Recent advances TAM heterogeneity, characterization, immunological responses, therapy described here. The manuscript details functions their role resistance to PD-1/PD-L1 blockade. Similarly, TAM-targeted approaches, such as CSF-1R inhibition PI3Kγ-driven reprogramming, discussed address immunity suppression. Furthermore, innovative biomarkers combination may enhance TAM-centric therapies. It also stresses relevance of this distinct cell human health disease, which could impact future research

Language: Английский

Impact of Helicobacter pylori infection status on outcomes among patients with gastric cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis DOI
Francisco Cézar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Francinny Alves Kelly

et al.

Microbial Pathogenesis, Journal Year: 2025, Volume and Issue: unknown, P. 107407 - 107407

Published: Feb. 1, 2025

Language: Английский

Citations

0
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia DOI Creative Commons

Hui-Sheng Zhou,

Yong-Feng Su,

Jun Wang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 17, 2025

Anti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab a hypomethylating agent (HMA) plus CAG regimen treating r/r AML, an increased sample size comparison, historical control group for more reliable data support (ClinicalTrials.gov identifier NCT04541277). The included total 37 AML who received + HMA regimen. overall response rate was 69.4%, median survival 12.1 months event-free 6.2 months. Multivariate analysis revealed that aged 40 or above exhibited higher rate, while those lower burden (bone marrow blast percentage <40%) demonstrated improved survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation associated extended Grade 2-3 immune-related adverse events were observed 8.5% patients, no deaths directly attributed these events. After propensity score matching, inclusion appeared positively influence compared controls treated Overall, combination rates maintaining low incidence severity patients. https://clinicaltrials.gov/, NCT04541277.

Language: Английский

Citations

0
Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy DOI

Donya Esmaeilpour,

Matineh Ghomi, Ehsan Nazarzadeh Zare‬

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 12, 2025

RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.

Language: Английский

Citations

0
Immunopharmacology of gastric cancer–deciphering immune cell subset responses and nanoparticle-mediated targeting DOI Creative Commons
Yanting Wang, Ning Ding, Lina Qi

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 19, 2025

The diverse landscape of immune cell populations significantly influences therapeutic outcomes in advanced gastric cancer, a leading cause cancer mortality worldwide. Progress immunopharmacology, aided by single-cell analytics, increasingly highlights complexity and functional heterogeneity. Conventional categories contain subsets, including various T cells (helper, regulatory, memory) B (plasma, memory, regulatory). Innate like macrophages, natural killer cells, dendritic also exist states. These subsets exhibit distinct pharmacological response profiles that are often obscured bulk analyses. This review explores the differential responses critical within tumor microenvironment to current modalities, encompassing cytotoxic chemotherapy, molecular targeted agents, immunotherapies such as checkpoint inhibitors. We delve into processes underlying subset-specific drug effects, potential mechanisms resistance linked specific states, influence on subset pharmacology. Furthermore, we discuss application nanoparticle-based delivery systems specifically engineered target subpopulations, aiming enhance immunomodulatory efficacy, reshape repertoires favorably, overcome resistance, minimize toxicity for more precise effective treatment cancer.

Language: Английский

Citations

0
Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy DOI Creative Commons
Abdullah F. U. H. Saeed

Cells, Journal Year: 2025, Volume and Issue: 14(10), P. 741 - 741

Published: May 19, 2025

Tumor-associated macrophages’ (TAMs) origin, polarization, and dynamic interaction in the tumor microenvironment (TME) influence cancer development. They are essential for homeostasis, monitoring, immune protection. Cells from bone marrow or embryonic progenitors dynamically polarize into pro- anti-tumor M2 M1 phenotypes based on cytokines metabolic signals. Recent advances TAM heterogeneity, characterization, immunological responses, therapy described here. The manuscript details functions their role resistance to PD-1/PD-L1 blockade. Similarly, TAM-targeted approaches, such as CSF-1R inhibition PI3Kγ-driven reprogramming, discussed address immunity suppression. Furthermore, innovative biomarkers combination may enhance TAM-centric therapies. It also stresses relevance of this distinct cell human health disease, which could impact future research

Language: Английский

Citations

0